FR2182914A1 - - Google Patents

Info

Publication number
FR2182914A1
FR2182914A1 FR7311419A FR7311419A FR2182914A1 FR 2182914 A1 FR2182914 A1 FR 2182914A1 FR 7311419 A FR7311419 A FR 7311419A FR 7311419 A FR7311419 A FR 7311419A FR 2182914 A1 FR2182914 A1 FR 2182914A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7311419A
Other languages
French (fr)
Other versions
FR2182914B1 (cs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of FR2182914A1 publication Critical patent/FR2182914A1/fr
Application granted granted Critical
Publication of FR2182914B1 publication Critical patent/FR2182914B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR7311419A 1972-03-30 1973-03-29 Expired FR2182914B1 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP47032033A JPS5229318B2 (cs) 1972-03-30 1972-03-30

Publications (2)

Publication Number Publication Date
FR2182914A1 true FR2182914A1 (cs) 1973-12-14
FR2182914B1 FR2182914B1 (cs) 1976-05-14

Family

ID=12347544

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7311419A Expired FR2182914B1 (cs) 1972-03-30 1973-03-29

Country Status (12)

Country Link
US (1) US3850941A (cs)
JP (1) JPS5229318B2 (cs)
AR (1) AR197709A1 (cs)
BE (1) BE797554A (cs)
BR (1) BR7302268D0 (cs)
CA (1) CA989843A (cs)
DE (1) DE2315801C3 (cs)
ES (1) ES413188A1 (cs)
FR (1) FR2182914B1 (cs)
GB (1) GB1378375A (cs)
HU (1) HU167305B (cs)
SE (1) SE402592B (cs)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2289192A1 (fr) * 1974-11-01 1976-05-28 Kyorin Seiyaku Kk Pyrazolo(1,5-a)pyridines et medicament contenant ces substances
EP0215438A3 (en) * 1985-09-14 1989-05-24 Kyorin Seiyaku Kabushiki Kaisha Use of 3-isobutyryl-2-isopropylpyrazoloû1,5-a¨pyridine as an anti-rheumatic agent
EP0319902A3 (en) * 1987-12-10 1990-01-31 Kyorin Seiyaku Kabushiki Kaisha Transdermal absorptive drug formulation
EP0355234A1 (en) * 1988-08-25 1990-02-28 Merrell Dow Pharmaceuticals Inc. Pyrazolopyridine derivatives as antiatherosclerotic and antihypercholesterolemic agents

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097483A (en) * 1974-11-01 1978-06-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolo 1,5-a!pyridines
US4237300A (en) * 1975-12-09 1980-12-02 Merck & Co., Inc. Certain 6-substituted-2-pyridinamines
JPS5968553A (ja) * 1982-10-13 1984-04-18 Automob Antipollut & Saf Res Center 燃料タンク内蔵式燃料ポンプ
JPS6072975U (ja) * 1983-10-26 1985-05-22 ヤンマーディーゼル株式会社 燃料ポンプのエア抜き装置
JPH0621066B2 (ja) * 1984-03-14 1994-03-23 杏林製薬株式会社 ３―イソブチリル―２―イソプロピルピラゾロ〔１，５―ａ〕ピリジンの徐放性医薬品組成物
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
JPH085790B2 (ja) * 1988-11-11 1996-01-24 杏林製薬株式会社 記憶障害改善薬
JPH0256853U (cs) * 1989-10-04 1990-04-24
JPH06166687A (ja) * 1990-07-18 1994-06-14 Senju Pharmaceut Co Ltd ピラゾロ〔１，５−ａ〕ピリジン化合物、その製造法および用途
ATE320800T1 (de) 1999-08-21 2006-04-15 Altana Pharma Ag Synergistische kombination von roflumilast und salmeterol
ATE502635T1 (de) 2002-08-19 2011-04-15 Pfizer Kombinationstherapie gegen hyperproliferative erkrankungen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
KR20110117731A (ko) 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의 용도
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
AU2004292445B2 (en) 2003-11-21 2010-02-04 Zalicus Inc. Methods and reagents for the treatment of inflammatory disorders
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP1948599A1 (en) 2005-11-08 2008-07-30 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
TWI435729B (zh) 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法，組合物及套組
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7585875B2 (en) 2006-06-06 2009-09-08 Avigen, Inc. Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
PL2131841T3 (pl) 2007-01-30 2013-03-29 Avigen Inc Sposoby leczenia bólu ostrego
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US7536799B2 (en) * 2007-06-07 2009-05-26 Keson Industries Chalk line apparatus with strategically located chalk fill opening
US20100226881A1 (en) * 2007-07-11 2010-09-09 Auckland Uniservices Limited PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY
WO2009023179A2 (en) * 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
CA2696041A1 (en) * 2007-08-15 2009-02-19 Kyorin Pharmaceutical Co., Ltd. Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010005520A2 (en) * 2008-06-30 2010-01-14 Concert Pharmaceuticals, Inc. 2-alkyl-3-acylpyrazolo[1,5-a]pyridine derivatives
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8455477B2 (en) * 2008-08-05 2013-06-04 Merck Sharp & Dohme Corp. Therapeutic compounds
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
WO2011059053A1 (ja) 2009-11-13 2011-05-19 東レ株式会社 糖尿病の治療または予防薬
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2828346C (en) 2011-03-01 2021-01-26 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
ES2395801B1 (es) 2011-06-23 2014-06-06 María Carmen PARDINA PALLEJÀ "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad"
CN102617579A (zh) * 2012-03-28 2012-08-01 黑龙江大学 一种异丁司特的制备方法
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
CN114404588A (zh) 2013-08-09 2022-04-29 阿德利克斯公司 用于抑制磷酸盐转运的化合物和方法
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CN108033959A (zh) * 2018-01-29 2018-05-15 山东省药学科学院 一种异丁司特的化学合成方法
PL3911648T3 (pl) 2019-01-18 2025-03-10 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluorometoksy)-2- pirymidynylo]amino]cyklopentylo]amino][1(2h),3'-bipirydyn]-2-on jako inhibitor pcsk9 i sposoby jego zastosowania
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport
CN113387947B (zh) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 调节雌激素受体合成活性的吡唑并吡啶衍生物
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2289192A1 (fr) * 1974-11-01 1976-05-28 Kyorin Seiyaku Kk Pyrazolo(1,5-a)pyridines et medicament contenant ces substances
EP0215438A3 (en) * 1985-09-14 1989-05-24 Kyorin Seiyaku Kabushiki Kaisha Use of 3-isobutyryl-2-isopropylpyrazoloû1,5-a¨pyridine as an anti-rheumatic agent
EP0319902A3 (en) * 1987-12-10 1990-01-31 Kyorin Seiyaku Kabushiki Kaisha Transdermal absorptive drug formulation
US5602165A (en) * 1987-12-10 1997-02-11 Kyorin Seiyaku Kabushiki Kaisha Transdermal absorptive drug formulation
EP0355234A1 (en) * 1988-08-25 1990-02-28 Merrell Dow Pharmaceuticals Inc. Pyrazolopyridine derivatives as antiatherosclerotic and antihypercholesterolemic agents

Also Published As

Publication number Publication date
AU5376173A (en) 1974-09-26
US3850941A (en) 1974-11-26
AR197709A1 (es) 1974-04-30
DE2315801B2 (de) 1978-06-22
JPS4897898A (cs) 1973-12-13
SE402592B (sv) 1978-07-10
BE797554A (fr) 1973-07-16
HU167305B (cs) 1975-09-27
DE2315801A1 (de) 1973-10-11
CA989843A (en) 1976-05-25
FR2182914B1 (cs) 1976-05-14
BR7302268D0 (pt) 1974-08-29
JPS5229318B2 (cs) 1977-08-01
GB1378375A (en) 1974-12-27
DE2315801C3 (de) 1979-02-22
ES413188A1 (es) 1976-01-16

Similar Documents

Publication Publication Date Title
FR2182914A1 (cs)
CS172269B2 (cs)
CS165380B2 (cs)
CS159520B1 (cs)
CS166335B1 (cs)
CS165060B1 (cs)
CS163975B1 (cs)
CS163950B1 (cs)
CS163866B1 (cs)
CS155560B1 (cs)
CS162910B1 (cs)
CS166333B1 (cs)
CS161378B1 (cs)
CS159496B1 (cs)
CS159480B1 (cs)
CS158837B1 (cs)
CS157946B1 (cs)
CS157938B1 (cs)
CS155629B1 (cs)
CH571915A5 (cs)
CH576085A5 (cs)
CH580921A5 (cs)
CH581789A5 (cs)
CH582211A5 (cs)
CH583155A5 (cs)